A case of Vogt-Koyanagi-Harada disease associated with malignant lymphoma

Japanese Journal of Ophthalmology

Volumn 49, Issue 3, 2005, Pages 253-256

  Hashida, Noriyasu ^a   Kanayama, Shintaro ^b   Kawasaki, Atsushi ^b   Ogawa, Kenji ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b TOYONAKA MUNICIPAL HOSPITAL   (Japan)

Author keywords

Malignant lymphoma; Soluble interleukin 2 receptor; Vogt Koyanagi Harada disease

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE; VINCRISTINE;

ABDOMINAL RADIOGRAPHY; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; HUMAN; INFLAMMATION; LARGE CELL LYMPHOMA; MALE; MEDICAL EXAMINATION; OPHTHALMOSCOPY; PAPILLEDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA DETACHMENT; SPINE METASTASIS; THORAX RADIOGRAPHY; VISION TEST; VISUAL ACUITY; VISUAL IMPAIRMENT; VOGT KOYANAGI SYNDROME;

AGED; HUMANS; LYMPHOMA; MALE; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, INTERLEUKIN-2; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY;

EID: 21144441215     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-004-0177-5     Document Type: Article

References (10)

1. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995;39:265-292.
2. Norose K, Yano A. Melanoma-specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 1996;80:1002-1008.
3. Ohno H, Ishikawa T, Kitajima H, Nomura S, et al. Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study. Rinsho Ketsueki 2002;43:170-175.
4. Symons JA, Wood NC, Di Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988;141:2612-2618.
5. Murray PI, Young DW. Soluble interleukin-2 receptors in retinal vasculitis. Curr Eye Res 1992;11(Suppl):193-195.
6. Alpsoy E, Cayirli C, Er H, Yilmaz E. The levels of plasma interleukin-2 and soluble interleukin-2R in Behçet's disease: a marker of disease activity. J Dermatol 1998;25:513-516.
7. Uchio E, Matsumoto T, Tanaka SI, Ohno S. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. Clin Exp Rheumatol 1999;17:179-184.
8. Kogiso M, Tanouchi Y, Miki S, Mimura Y. Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1992;36:37-43.
9. Ernst BB, Lowder CY, Meisler DM, Gutman FA. Posterior segment manifestations of inflammatory bowel disease. Ophthalmology 1991;98:1272-1280.
10. Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S. Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease. Curr Eye Res 2001;22:312-318.